Monte Rosa Therapeutics, Inc. announced that Owen Wallace, Ph.D., the Company?s Chief Scientific Officer will be departing from his position to transition to a Chief Executive Officer role at a UK-based biotechnology company. Dr. Wallace will serve as a scientific advisor to Monte Rosa, including as a member of its Scientific Advisory Board (SAB).
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
4.435 USD | +3.26% | -14.10% | -23.98% |
May. 16 | Sector Update: Health Care Stocks Mixed in Late Afternoon Trading | MT |
May. 16 | Monte Rosa Therapeutics Prices $100 Million Public Offering | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-23.98% | 263M | |
+44.48% | 55.07B | |
-0.86% | 41.79B | |
+44.19% | 40.22B | |
-7.59% | 28.17B | |
+12.30% | 26.28B | |
-21.83% | 18.93B | |
+7.15% | 13.03B | |
+29.40% | 12.26B | |
+25.15% | 12.21B |
- Stock Market
- Equities
- GLUE Stock
- News Monte Rosa Therapeutics, Inc.
- Monte Rosa Therapeutics, Inc. Announces Departure of Owen Wallace as Chief Scientific Officer and Transition to Member of its Scientific Advisory Board